# Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

> **NCT02039765** · PHASE1 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 12 (actual)

## Conditions studied

- Hyperemia

## Interventions

- **DRUG:** Brimonidine tartrate

## Key facts

- **NCT ID:** NCT02039765
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039765, "Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02039765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*